Aripiprazole-Induced Improvement in Tardive Dyskinesia

Duggal, Harpreet S.

doi:10.1177/070674370304801116

Cited by 50 publications

(30 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some case reports also found aripiprazole-induced improvement in tardive dyskinesia [13]. Here, in this case, we found aripiprazole-induced rabbit syndrome and adding an anticholinergic led to discontinuation of symptoms.…”

Section: Casesupporting

confidence: 58%

Aripiprazole-Induced Rabbit Syndrome: How Safe is Its Use in Adolescence?

Dey¹,

Kalita²

2016

J Depress Anxiety

View full text Add to dashboard Cite

Section: Casesupporting

confidence: 58%

Aripiprazole-Induced Rabbit Syndrome: How Safe is Its Use in Adolescence?

Dey¹,

Kalita²

2016

J Depress Anxiety

View full text Add to dashboard Cite

“…As a dopamine autoreceptor partial agonist, aripiprazole causes a minimal or no change in serum prolactin. Alternately, in one reported case, institution of aripiprazole led to resolution of chronic (2 year's duration) haloperidol-induced tardive dyskinesia which had been refractory to six other atypical agents (8). Moreover, at high doses most of the atypical antipsychotic drugs (except clozapine) lose their atypical features and are associated with EPS (e.g., risperidone at >6 mg/dose) (9).…”

Section: Mechanism Of Actionmentioning

confidence: 96%

Aripiprazole (Abilify™) Overdose in a Child

Seifert¹,

Schwartz²,

Thomas³

2005

LCLT

View full text Add to dashboard Cite

Aripiprazole, 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl] butyloxy}-3,4-dihydro-2(1H)-quinolinone, is an atypical antipsychotic medication inaugurating the newest class of atypical antipsychotics: the partial dopamine agonists. It has a particularly long half-life of elimination and variable metabolism secondary to genetic polymorphism. We report an unintentional overdose of 195 mg (17.1 mg/kg) of aripiprazole in a 2.5 year-old child. This patient exhibited CNS depression not requiring respiratory support and without significant cardiovascular effects. CNS effects persisted for almost 2 weeks postingestion.

show abstract

“…To date, one case report (27) presented the effective use of aripiprazole in a treatment-resistant patient with schizoaffective disorder who had significant tardive dyskinesia (TD). The patient was started on 15 mg daily and raised to 30 mg daily after two weeks.…”

Section: Schizophrenia and Related Disordersmentioning

confidence: 99%

Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology

2004

View full text Add to dashboard Cite

Aripiprazole (Abilify ® ) is an atypical antipsychotic drug that has been recently introduced for clinical use in the treatment of schizophrenia. Aripiprazole has a unique pharmacologic profile that includes partial agonism at several G-protein coupled receptors (GPCRs) [especially dopamine (D 2 ) and 5-HT 1A ] and antagonistic action at others (especially 5-HT 2A ). Clinical trials indicate that aripiprazole is effective in treating the positive and negative symptoms of schizophrenia. In short-term studies rapid onset of action (within one week) has been demonstrated. Preliminary data indicate that aripiprazole may also be effective in the treatment of manic symptoms of bipolar disorder. At recommended doses, aripiprazole appears to be safe and well tolerated in most adult patients with schizophrenia and schizoaffective disorder. There is only limited information available on the use of aripiprazole in children and adolescents, and pilot data suggest that a revised dosing strategy, based on weight, is indicated in this population. In the long-term studies, the use of aripiprazole was associated with continued efficacy, good compliance and increased time-to-relapse.Aripiprazole represents the first functionally selective atypical antipsychotic drug.

show abstract

Aripiprazole-Induced Improvement in Tardive Dyskinesia

Abstract: Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania.

Cited by 50 publications

References 5 publications

Aripiprazole-Induced Rabbit Syndrome: How Safe is Its Use in Adolescence?

Aripiprazole-Induced Rabbit Syndrome: How Safe is Its Use in Adolescence?

Aripiprazole (Abilify™) Overdose in a Child

Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology

Contact Info

Product

Resources

About